Elsevier

The Lancet

Volume 304, Issue 7890, 16 November 1974, Pages 1208-1209
The Lancet

Letters to the Editor
DOUBLE-BLIND TRIAL OF LITHIUM CARBONATE AND HALOPERIDOL IN HUNTINGTON'S CHOREA

https://doi.org/10.1016/S0140-6736(74)90847-2Get rights and content

References (8)

  • P. Dalen

    Lancet

    (1973)
  • B. Mattsson

    Lancet

    (1973)
  • N.V.B. Manyam et al.

    Lancet

    (1973)
  • B. Mattsson et al.

    Lancet

    (1973)
There are more references available in the full text version of this article.

Cited by (20)

  • Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

    2010, Pharmacology and Therapeutics
    Citation Excerpt :

    However, some other reports showed that lithium exerted no beneficial effects in HD patients (Aminoff & Marshall, 1974; Vestergaard et al., 1977). In some instances, lithium treatment even worsened motor and cognitive performance, particularly when used as the sole therapeutic agent (Carman et al., 1974; Leonard et al., 1974). Nonetheless, it should be noted that the number of patients included in those trials was small, and the duration of lithium treatment was also too short to assess the potential benefit of this drug.

  • Clinical Features and Care

    2010, Blue Books of Neurology
    Citation Excerpt :

    Physical and occupational therapies are sensible, but there are no controlled studies of benefit. Agents that block postsynaptic dopamine receptors (e.g., fluphenazine,143 haloperidol144) are generally effective in suppressing chorea, but treatment is often associated with nagging long-term risks of promoting superimposed tardive dyskinesia and the more immediate adverse effects of dysphoria, apathy, and bradykinesia. The so-called atypical antipsychotic drugs might be expected to lessen chorea; however, only clozapine has been subjected to short-term rigorous assessment and with weak results.145

  • A review of clinical trials of lithium in neurology

    1984, Pharmacology, Biochemistry and Behavior
  • Huntington’s Disease—Update on Treatments

    2017, Current Neurology and Neuroscience Reports
View all citing articles on Scopus
View full text